Clinical Trials Browser

Phase 1/2 × Melanoma × Interleukin-2 × Clear all

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06961357 2025-12-03

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

Melanoma

NCT03374839 2022-05-06

Nivo-TIL

Phase 1/2 Unknown

Melanoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

13 enrolled 12 charts

Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

12 enrolled 10 charts

Melanoma

NCT03111901 2019-07-12

UVA-AM-002

Phase 1/2 Withdrawn

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT00062036 2017-07-02

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT00871481 2017-04-19

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT01273181 2015-10-28

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Phase 1/2 Terminated

9 enrolled 13 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00937625 2015-08-18

T-cell Based Immunotherapy for of Melanoma

Phase 1/2 Completed

Melanoma

NCT01743157 2013-08-29

BBI

Phase 1/2 Completed

Melanoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Phase 1/2 Withdrawn

Melanoma

NCT00197912 2010-04-26

Dendritic Cell Based Therapy of Malignant Melanoma

Phase 1/2 Completed

Melanoma